Related Experiment Videos
Epstein-Barr virus and bone marrow transplantation
1Johns Hopkins Oncology Center, Baltimore, Maryland, USA.
Current Opinion in Oncology
|March 1, 1995
Summary
Epstein-Barr virus-associated posttransplantation lymphoproliferative disease (EBV-PTLD) risk increases with viral load. Adoptive cellular immunotherapy offers a promising treatment approach for EBV-PTLD.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Epstein-Barr virus (EBV) reactivation post-transplantation can lead to posttransplantation lymphoproliferative disease (PTLD).
- EBV-PTLD development correlates with increased viral burden in lymphocytes and complex viral gene expression patterns.
- Conventional chemotherapy for EBV-PTLD offers variable long-term disease-free survival.
Purpose of the Study:
- To review current understanding and emerging therapeutic strategies for Epstein-Barr virus-associated posttransplantation lymphoproliferative disease.
- To highlight the potential of adoptive cellular immunotherapy as a novel treatment modality.
Main Methods:
- Literature review of studies on EBV-PTLD pathogenesis, diagnosis, and treatment.
- Analysis of data on conventional chemotherapy, adoptive cellular immunotherapy, and allogeneic bone marrow transplantation outcomes.
Main Results:
- Increased viral burden in lymphocytes is a key factor in EBV-PTLD development.
- Adoptive cellular immunotherapy using donor lymphocytes or T-cell lines shows promise.
- Allogeneic bone marrow transplantation has demonstrated success in specific patient populations.
Conclusions:
- EBV-PTLD management requires tailored approaches considering viral load and immune status.
- Adoptive cellular immunotherapy represents a significant advancement in treating EBV-PTLD.
- Further research into immune-based therapies is crucial for improving patient outcomes.